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Abstract
Background: We report an attempt to extend the previously successful approach of combining SNP (single
nucleotide polymorphism) microarrays and DNA pooling (SNP-MaP) employing high-density microarrays. Whereas
earlier studies employed a range of Affymetrix SNP microarrays comprising from 10 K to 500 K SNPs, this most
recent investigation used the 6.0 chip which displays 906,600 SNP probes and 946,000 probes for the interrogation
of CNVs (copy number variations). The genotyping assay using the Affymetrix SNP 6.0 array is highly demanding
on sample quality due to the small feature size, low redundancy, and lack of mismatch probes.
Findings: In the first study published so far using this microarray on pooled DNA, we found that pooled cheek swab
DNA could not accurately predict real allele frequencies of the samples that comprised the pools. In contrast, the allele
frequency estimates using blood DNA pools were reasonable, although inferior compared to those obtained with
previously employed Affymetrix microarrays. However, it might be possible to improve performance by developing
improved analysis methods.
Conclusions: Despite the decreasing costs of genome-wide individual genotyping, the pooling approach may
have applications in very large-scale case-control association studies. In such cases, our study suggests that high-
quality DNA preparations and lower density platforms should be preferred.
Background
We report an attempt to extend the previously successful
approach of SNP (single nucleotide polymorphism)
microarrays and DNA pooling (SNP-MaP) [1-14].
Whereas earlier studies had employed a range of Affyme-
trix SNP microarrays interrogating between 10 K to 500
K SNPs [15], we used the Affymetrix SNP 6.0 which dis-
plays 906,600 SNP probes and 946,000 probes for the
interrogation of CNVs (copy number variations). We
have performed this genome-wide association study
(GWAS) using pooled DNA from a large depression
case-control sample (1418 cases, 1301 controls), and the
SNPs with the largest differences between cases and con-
trols were individually genotyped in the sample used to
construct the pools. In contrast to the suitability of Affy-
metrix microarrays (up to the 500 K) for successful ana-
l y s i so fD N Ap o o l sa se s t a b l i s h e db yo t h e rg r o u p s ,t h e
properties of the Affymetrix SNP 6.0 used in the current
study were unproven at the time of investigation.
Methods
Study design
GWAS using phenotypically standardised pooled DNA
of a large depression case-control (DeCC) sample was
followed-up by individually genotyping the ‘top-hit’
SNPs. The SNP-MaP approach was conducted with the
Affymetrix Genome-Wide Human SNP Array 6.0, con-
taining approximately 1 million SNP markers [1].
Samples
Our depression case-control (DeCC) samples of 1418
patients with a diagnosis of recurrent major depression
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three clinical sites in UK (London, Cardiff and Bir-
mingham) as described previously [16]. All participants
gave written informed consent, and the study was
approved by the Local Ethical Committees of the three
centres.
DNA pooling
Blood samples were obtained from all patients and
either blood or buccal mucosa swabs obtained from
controls. Genomic DNA was extracted by an in-house
validated procedure as described previously [17,18].
Genomic DNA was quantified three times using Pico-
Green® assay (Molecular Probes, Eugene, OR, USA).
The DNA pools of the DeCC sample were created as
follows: first of all, the sample was divided into cases
and controls, and then into males and females. Subse-
quently, these groups were divided according to their
body mass index (BMI <25, BMI 25-30, BMI >30) in
the light of phenotypic analyses of DeCC, showing
strong associations between depression and various
physical diseases mediated via increased BMI [19]. We
randomly created 57 DNA-pools of on average 47.67
individuals of matched sex and phenotype (SD = 9.39),
and each individual contributed 100 ng DNA to their
pools which ranged in concentrations from 19.0 to
24.99 ng/μL.
Allelotyping the DNA pools
The Affymetrix Genome-Wide Human SNP Array 6.0 in
combination with the standard Affymetrix protocol was
used to allelotype 200 ng genomic DNA from each pool.
Water was used as a negative control to test for contami-
nation, and to test for assay performance, the manufac-
turer’s individual reference DNA was used as a positive
control. Three pools were genotyped in duplicate, serving
as technical replicates.
Generating RAS (relative allele signal) scores
In contrast to the earlier versions of Affymetrix geno-
typing arrays, the latest SNP arrays (Affymetrix Gen-
ome-Wide SNP Array 5.0 and 6.0; but not the
previously employed 500 K chip) differ in that the mis-
match probes have been discarded in favour of greater
perfect match probe density. Thus, mismatch intensi-
ties can no longer be subtracted before calculating
RAS scores, and RAS scores based on an equivalent
principle to those that have been validated for pooling
in previous work cannot, therefore, be calculated any-
more. As a consequence they may no longer represent
a good estimate of the absolute allele frequency in the
pool; however, such estimates may still be useful for
detecting frequency differences between pools [20].
Confirmatory individual genotyping
Confirmatory individual genotyping was performed
using the Sequenom MassARRAY® iPLEX Gold assay
and TaqMan® SNP genotyping platform.
Statistical analyses
Cell intensity (.CEL) files were exported and RAS scores
generated from the cell intensity data using the RAS
score algorithm as implemented in a freely available
script in R (http://sgdp.iop.kcl.ac.uk/oleo/affy), which
has now become part of an R package, the SNPMaP
package [21]. To test for significant differences between
cases and controls, an independent Student’st - T e s tw a s
applied using R statistical software (http://www.r-pro-
ject.org/).
Results
We have performed a genome-wide association study
(GWAS) using pooled DNA of a depression case-control
sample and the Affymetrix Genome-Wide Human SNP
Array 6.0, and followed-up the ‘top-hit’ SNPs using con-
firmatory individual genotyping with Sequenom Mas-
sARRAY® iPLEX Gold or TaqMan®. Three DNA-pools
were genotyped in duplicate and hybridized to two sepa-
rate microarrays (’technical replicates’). The pairwise
correlations were 0.945, 0.965 and 0.967 respectively.
Biological replicates (pools of the same phenotypic
group) were available for the majority of pools in the
current study. We randomly selected five blood DNA
case-pools of the same phenotypic group (cases, females,
body-mass-index 25 to 30) and found an average pair-
wise correlation of 0.956; we found similar average pair-
wise correlations (0.959) for four cheek-swab-DNA
control pools of the same phenotypic group (controls,
females, body-mass-index less than 25) and four blood
DNA control-pools of the same phenotypic group
(0.967) (controls, females, body-mass-index less than
25). We allelotyped a total of 57 DNA pools of on aver-
age 47.67 individuals each (SD = 9.39), 29 pools of cases
and 28 pools of controls. All case-pools contained blood
DNA, whereas only 10 control-pools contained blood
DNA, the remainder (18) contained cheek swab DNA.
To test for significant differences in allele frequencies
between cases and controls, an independent Student’st -
Test was applied and after excluding rare variants with
a minor allele frequency (MAF) <0.05, we found 74
SNPs crossing the genome-wide significance threshold
of 7.2 × 10
-8 [22]. The top-ranked SNPs of the pooling
GWAS were followed-up by individually genotyping the
samples used to construct the pools, and the validity of
the SNP-MaP approach was assessed by comparing
allele frequency estimates from pooled DNA (RAS
scores) with individual genotyping data of 110 SNPs
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Gold (108 SNPs) or TaqMan® (2 SNPs). We performed
these analyses for cases and controls separately and,
since all case pools contained blood DNA but 18 out of
28 control pools contained cheek swab DNA, we divided
the controls into two groups according to source of
DNA. The Pearson’s correlation of the allele frequency
estimates of the DNA pools (RAS scores) and the ‘real’
allele frequencies derived from individual genotyping
was 0.9010 for the case-pools (all blood DNA) and
0.8853 for the blood DNA control-pools; however, the
correlation was only 0.2734 for the cheek swab control-
pools (see Figure 1).
Conclusions
The current study was an attempt to extend the pre-
viously successful approach of SNP microarrays and
DNA pooling (SNP-MaP) to a whole-genome associa-
tion study of MDD employing high-density microarrays.
Whereas the earlier studies had employed a range of
Affymetrix SNP microarrays comprising from 10 K to
500 K SNPs, this most recent investigation used the 6.0
chip, which displays 906,600 SNP probes and 946,000
probes for the interrogation of CNVs. The main advan-
tage of DNA pooling is that it is a way to reduce costs
in determining allele frequencies in large case/control
cohorts. Since individual genotypes cannot be deter-
mined, this process is called “allelotyping” and it enables
allele frequency differences between pools comprised
DNA from many individuals to be compared without
the need to genotype each individual.
For the purposes of allelotyping pooled DNA, there
are three subtle but potentially detrimental changes dif-
ferentiating the Affymetrix SNP 6.0 microarray from its
validated 10 K, 100 K and 500 K predecessors. First, the
feature size has decreased from 18 μm on the 10 K, to 8
μmo nt h e1 0 0K ,a n dt o5μmo nt h e5 0 0Ka n dA f f y -
metrix SNP 6.0 microarrays. Second, each SNP is inter-
rogated by 40 probes on the Affymetrix 10 K and 100
K, 24 probes for 90% of the Affymetrix 500 K, but by
only 6-8 probes on the Affymetrix SNP 6.0 microarray.
Third, the mismatch probes have been discarded from
the Affymetrix SNP 6.0 microarray, and thus mismatch
probe intensities cannot be subtracted from perfect
match probe intensities as it was the case for previous
Affymetrix microarrays up to the 500 K. To our knowl-
edge, this is the first study published so far using the
Affymetrix SNP 6.0 microarray on pooled DNA.
W ec r e a t e d5 7D N Ap o o l so ft h eD e C Cs a m p l e ,e a c h
containing equal amounts of DNA of on average 47.67
individuals (SD = 9.39).
We assessed validity of the genome-wide pooling
study by comparing the estimates of allele frequencies
from pooled DNA with individual genotyping data of
110 SNPs genotyped with either Sequenom MassAR-
RAY® iPLEX Gold or TaqMan®, and allele frequency
estimates provided by Affymetrix NetAffx™ (http://www.
affymetrix.com/analysis/index.affx). While there was a
high correlation (>0.99) between allele frequencies
derived from confirmatory individual genotyping and
the allele frequencies provided by Affymetrix NetAffx™,
the correlation between the allele frequency estimates
derived from the pools (RAS scores) and the ‘real’ allele
frequencies derived from individually genotyping the
samples which composed the pools was somewhat dis-
appointing. Although the correlation of RAS scores and
‘real’ allele frequencies was reasonable (but rather poor
as compared to the previous Affymetrix microarrays up
to the 500 K) for the blood DNA cases (Pearson’s corre-
lation of 0.901) and the blood DNA controls (Pearson’s
correlation of 0.885), the correlation of cheek swab
DNA controls was only 0.273. The RAS scores produced
using the Affymetrix SNP 6.0 array have a different dis-
tribution than the conventional RAS scores that had
been validated for pooling in previous work, since the
mismatch probes have been discarded in favour of
greater perfect match probe intensity. Therefore, mis-
match intensities cannot be substracted before calculat-
ing RAS scores, and the ratio of allele signal intensities
A/(A+B) is calculated instead. As a consequence, the
RAS scores derived from the Affymetrix SNP 6.0 array
are not necessarily a good estimate of the absolute allele
frequency in the pool [21]. However, this should not
affect case-control comparison in a genome-wide pool-
ing study, since we are interested in frequency differ-
ences between the groups, not necessarily in absolute
allele frequencies. Although the RAS scores indeed did
not accurately predict the ‘real’ allele frequencies in our
sample, we hypothesized that the difference between
cases and controls are expected to be the same in the
p o o l sa si nt h ei n d i v i d u a l st h a tc o m p r i s et h ep o o l s .T o
test this hypothesis, we calculated the ratio of the mean
allele frequencies of controls and cases (controls/cases)
for the 110 SNPs individually genotyped, and the ratio
of the mean RAS scores of control and case pools (con-
trol pools/case pools) for the same SNPs genotyped on
the Affymetrix SNP 6.0 array. Subsequently, we calcu-
lated the ratio of the two ratios, where a ratio of 1
w o u l di n d i c a t et h a tt h em e a nc o n t r o l / c a s er a t i oo ft h e
RAS scores for a given SNP was a perfect estimate of
the ‘real’ ratio derived from individual genotyping of the
samples composing the pools. We found that the mean
of the latter ratios was 1.01 and the standard deviation
(SD) was 0.25, with 74.55% of SNPs within one SD. Per-
forming the same analyses after separating blood and
cheek swab controls, we found a mean of 0.99 and SD
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Page 3 of 6Figure 1 Pearson’s correlation of real allele frequencies (x-axis) and frequency estimates from pooled DNA (RAS-scores, y-axis) of
BACCS controls (a) (blood DNA) and the DeCC controls (b) (cheek swab DNA) are shown. The red arrows (a) indicate, that the distribution
of RAS scores (y-axis) are now slumped towards 0.5 as a consequence of the discarded mismatch probe (thus mismatch probe intensities cannot
be substracted from perfect match probe intensities) as compared to previous Affymetrix microarrays up to the 500 K. Pooled cheek swab DNA
(b) could not sufficiently predict ‘real’ allele frequencies of the samples that comprised the pools.
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Page 4 of 6of 0.11 in case of blood controls (89.09% of SNPs within
1 SD), and a mean of 1.05 and SD of 0.39 in case of
cheek swab controls (74% of SNPs within 1 SD).
These findings suggests that the microarray allelotyp-
ing cheek swab DNA pools did not sufficiently predict
‘real’ allele frequencies of the samples comprising the
pools (see Figure 1) even though the quality of cheek
swab DNA employed was comparable to that in pre-
vious studies. The genotyping assay using the Affymetrix
SNP 6.0 array is highly demanding on sample quality
due to the small feature size, low redundancy, and lack
of mismatch probes. In contrast to the problems
encountered with cheek swab DNA, the allele frequency
estimates using blood DNA pools on the 6.0 chip were
reasonable, although inferior compared to those
obtained with previous Affymetrix microarrays up to the
500 K chip. Nevertheless, knowing the nature of the
problems encountered and the differences in the organi-
sation of the probe features distinguishing the Affyme-
trix SNP 6.0 array from its predecessors, it might be
possible, however, to improve performance by develop-
ing improved analysis methods. In addition, despite the
decreasing costs of genome-wide individual genotyping,
the pooling approach with this (and other arrays) may
still be applicable in very large-scale case-control asso-
ciation studies, preferably using high-quality blood DNA
or a less SNP dense platform as appropriate.
Acknowledgements
Dr. Schosser was supported by an Erwin-Schrödinger-Fellowship (Ref. Nr.
J2647) of the Austrian Science Funds and by a NIHR South London and
Maudsley Biomedical Research Centre Preparatory Clinician Scientist
Fellowship. Dr. Gaysina was supported by INTAS Postdoctoral Fellowship
(Ref. Nr 04-83-3802) and Russian Science Support Foundation. The
depression case control collection (DeCC) was funded by the MRC UK. Dr.
Cohen-Woods was supported by a Medical Research Council (MRC) UK PhD
studentship and a NIHR South London and Maudsley Biomedical Research
Centre Postdoctoral Research Fellowship.
Author details
1MRC SGDP Centre, Institute of Psychiatry, King’s College London, London,
UK.
2Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Barts
and The London Medical School, Queen Mary University of London, London,
UK.
3Department of Psychiatry, University of Birmingham, Birmingham, UK.
4Division of Biological Psychiatry, Department of Psychiatry and
Psychotherapy, Medical University Vienna, Vienna, Austria.
Authors’ contributions
AS carried out the molecular genetic studies, the statistical analyses and
drafted the manuscript; KP performed pool construction and quantification;
DG participated in quantification and genotyping. SCW participated in pool
construction; LS supervised statistical analyses; AE, A, CG, JG and LJ
participated in sample collection; EM supervised microarray genotyping; AF,
IC and PM were principal investigators of the proposed study. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 June 2010 Accepted: 1 November 2010
Published: 1 November 2010
References
1. Butcher LM, Meaburn E, Liu L, Fernandes C, Hill L, Al-Chalabi A, et al:
Genotyping pooled DNA on microarrays: a systematic genome screen of
thousands of SNPs in large samples to detect QTLs for complex traits.
Behavior Genetics 2004, 34:549-555.
2. Butcher LM, Meaburn E, Knight J, Sham PC, Schalkwyk LC, Craig IW, et al:
SNPs, microarrays and pooled DNA: identification of four loci associated
with mild mental impairment in a sample of 6000 children. Hum Mol
Genet 2005, 14:1315-1325.
3. Butcher LM, Davis OSP, Craig IW, Plomin R: Genome-wide quantitative
trait locus association scan of general cognitive ability using pooled
DNA and 500 K single nucleotide polymorphism microarrays. Genes Brain
Behav 2008, 7:435-446.
4. Butcher LM, Plomin R: The Nature of Nurture: A Genomewide Association
Scan for Family Chaos. Behav Genet 2008, 38:361-371.
5. Bansal A, van den Boom D, Kammerer S, Honisch C, Adam G, Cantor CR,
et al: Association testing by DNA pooling: an effective initial screen. Proc
Natl Acad Sci USA 2002, 99(26):16871-16874.
6. Craig DW, Stephan DA: Applications of whole-genome high-density SNP
genotyping. Expert Rev Mol Diagn 2005, 5:159-170.
7. Craig JE, Hewitt AW, McMellon AE, Henders AK, Ma L, Wallace L, et al:
Rapid inexpensive genome-wide association using pooled whole blood.
Genome Res 2009, 19(11):2075-2080.
8. Johnson C, Drgon T, Liu QR, Walther D, Edenberg H, Rice J, et al: Pooled
association genome scanning for alcohol dependence using 104,268
SNPs: validation and use to identify alcoholism vulnerability loci in
unrelated individuals from the collaborative study on the genetics of
alcoholism. Am J Med Genet B Neuropsychiatr Genet 2006, 141B(8):844-853.
9. Liu QR, Drgon T, Johnson C, Walther D, Hess J, Uhl GR: Addiction
molecular genetics: 639,401 SNP whole genome association identifies
many “cell adhesion” genes. Am J Med Genet B Neuropsychiatr Genet 2006,
141B(8):918-925.
10. Kirov G, Nikolov I, Georgieva L, Moskvina V, Owen MJ, O’Donovan MC:
Pooled DNA genotyping on Affymetrix SNP genotyping arrays. BMC
Genomics 2006, 15:7-27.
11. Yang HC, Liang YJ, Huang MC, Li LH, Lin CH, Wu JY, et al: A genome-wide
study of preferential amplification/hybridization in microarray-based
pooled DNA experiments. Nucleic Acids Res 2006, 34(15):e106.
12. Steer S, Abkevich V, Gutin A, Cordell HJ, Gendall KL, Merriman ME, et al:
Genomic DNA pooling for whole-genome association scans in complex
disease: empirical demonstration of efficacy in rheumatoid arthritis.
Genes Immun 2007, 8(1):57-68.
13. Wilkening S, Chen B, Wirtenberger M, Burwinkel B, Försti A, Hemminski K,
et al: Allelotyping of pooled DNA with 250 K SNP microarrays. BMC
Genomics 2007, 8:77.
14. Shifman S, Bhomra A, Smiley S, Wray NR, James MR, Martin NG, et al: A
whole genome association study of neuroticism using DNA pooling. Mol
Psychiatry 2008, 13:302-312.
15. Meaburn E, Butcher LM, Liu L, Fernandes C, Hansen V, Al-Chalabi A, et al:
Genotyping DNA pools on microarrays: tackling the QTL problem of
large samples and large numbers of SNPs. BMC Genomics 2005, 6(1):52.
16. Schosser A, Gaysina D, Cohen-Woods S, Chow PC, Martucci L, Craddock N,
et al: Association of DISC1 and TSNAX genes and affective disorders in
the depression case-control (DeCC) and bipolar affective case-control
(BACCS) studies. Mol Psychiatry 2009.
17. Freeman B, Powell J, Ball D, Hill L, Craig I, Plomin R: DNA by mail: an
inexpensive and noninvasive method for collecting DNA samples from
widely dispersed populations. Behav Genet 1997, 27:251-257.
18. Freeman B, Smith N, Curtis C, Huckett L, Mill J, Craig IW: DNA from buccal
swabs recruited by mail: evaluation of storage effects on long-term
stability and suitability for multiplex polymerase chain reaction
genotyping. Behav Genet 2003, 33(1):67-72.
19. Farmer A, Korszun A, Owen MJ, Craddock , Jones L, Jones I, et al: Medical
disorders in people with recurrent depression. Br J Psychiatr 2008,
192:351-355.
20. Pearson JV, Huentelman MJ, Halperin RF, Tembe WD, Melquist S, Homer N,
et al: Identification of the genetic basis for complex disorders by use of
pooling-based genomewide single-nucleotide polymorphism association
studies. Am J Hum Genet 2007, 80:126-139.
Schosser et al. BMC Research Notes 2010, 3:274
http://www.biomedcentral.com/1756-0500/3/274
Page 5 of 621. Davis OS, Plomin R, Schalkwyk LC: The SNPMaP package for R: a
framework for genome-wide association using DNA pooling on
microarrays. Bioinformatics 2009, 25:281-283.
22. Dudbridge F, Gusnanto A: Estimation of significance thresholds for
genomewide association scans. Genet Epidem 2008, 32:227-234.
doi:10.1186/1756-0500-3-274
Cite this article as: Schosser et al.: Utility of the pooling approach as
applied to whole genome association scans with high-density
Affymetrix microarrays. BMC Research Notes 2010 3:274.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schosser et al. BMC Research Notes 2010, 3:274
http://www.biomedcentral.com/1756-0500/3/274
Page 6 of 6